These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 21609656)

  • 1. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
    Barnett AH
    Diabetes Obes Metab; 2012 Apr; 14(4):304-14. PubMed ID: 22051096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
    BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of the liraglutide clinical trial programme.
    Nauck MA
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
    Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide analogues for type 2 diabetes mellitus.
    Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
    Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
    Bruhn D; Martin AA; Tavares R; Hunt B; Pollock RF
    J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
    Zinman B; Schmidt WE; Moses A; Lund N; Gough S
    Diabetes Obes Metab; 2012 Jan; 14(1):77-82. PubMed ID: 21883806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.